BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11089880)

  • 1. Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen.
    Koutsilieris M; Lembessis P; Luu-The V; Sourla A
    Clin Exp Metastasis; 1999; 17(10):823-30. PubMed ID: 11089880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells.
    Zhang Y; Zippe CD; Van Lente F; Klein EA; Gupta MK
    Clin Cancer Res; 1997 Jul; 3(7):1215-20. PubMed ID: 9815802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer.
    Okegawa T; Noda H; Kato M; Miyata A; Nutahara K; Higashihara E
    Prostate; 2000 Aug; 44(3):210-8. PubMed ID: 10906737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer.
    Mitsiades CS; Lembessis P; Sourla A; Milathianakis C; Tsintavis A; Koutsilieris M
    Clin Exp Metastasis; 2004; 21(6):495-505. PubMed ID: 15679047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular staging of prostate cancer: comparison of nested reverse transcription polymerase chain reaction assay using prostate specific antigen versus prostate specific membrane antigen as primer.
    Okegawa T; Yoshioka J; Morita R; Nutahara K; Tsukada Y; Higashihara E
    Int J Urol; 1998 Jul; 5(4):349-56. PubMed ID: 9712443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients.
    Sourla A; Lembessis P; Mitsiades C; Dimopoulos T; Skouteris M; Metsinis M; Ntounis A; Ioannidis A; Katsoulis A; Kyragiannis V; Lambou T; Tsintavis A; Koutsilieris M
    Anticancer Res; 2001; 21(5):3565-70. PubMed ID: 11848524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage.
    Grasso YZ; Gupta MK; Levin HS; Zippe CD; Klein EA
    Cancer Res; 1998 Apr; 58(7):1456-9. PubMed ID: 9537248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
    Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
    J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
    Cama C; Olsson CA; Raffo AJ; Perlman H; Buttyan R; O'Toole K; McMahon D; Benson MC; Katz AE
    J Urol; 1995 May; 153(5):1373-8. PubMed ID: 7536252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
    Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J
    Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transrectal ultrasound-guided biopsy causes hematogenous dissemination of prostate cells as determined by RT-PCR.
    Moreno JG; O'Hara SM; Long JP; Veltri RW; Ning X; Alexander AA; Gomella LG
    Urology; 1997 Apr; 49(4):515-20. PubMed ID: 9111619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays.
    Israeli RS; Miller WH; Su SL; Powell CT; Fair WR; Samadi DS; Huryk RF; DeBlasio A; Edwards ET; Wise GJ
    Cancer Res; 1994 Dec; 54(24):6306-10. PubMed ID: 7527294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
    Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
    Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative nested reverse transcription-polymerase chain reaction for prostate specific membrane antigen predicts biochemical recurrence after radical prostatectomy.
    Okegawa T; Nutahara K; Higashihara E
    BJU Int; 1999 Jul; 84(1):112-7. PubMed ID: 10444137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular detection of prostate cells in ejaculate and urethral washings in men with suspected prostate cancer.
    Clements JA; Rohde P; Allen V; Hyland VJ; Samaratunga ML; Tilley WD; Lavin MF; Gardiner RA
    J Urol; 1999 Apr; 161(4):1337-43. PubMed ID: 10081904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The application of the RT-PCR method for the staging of the prostate cancer progression.
    Zummerova A; Labas P; Bohmer D; Blasko M; Polak S; Danisovic L; Repiska V
    Gen Physiol Biophys; 2010 Dec; 29(4):362-72. PubMed ID: 21156999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
    Schmittgen TD; Teske S; Vessella RL; True LD; Zakrajsek BA
    Int J Cancer; 2003 Nov; 107(2):323-9. PubMed ID: 12949815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer.
    Gao CL; Maheshwari S; Dean RC; Tatum L; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW
    Urology; 1999 Apr; 53(4):714-21. PubMed ID: 10197846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization.
    Gala JL; Heusterspreute M; Loric S; Hanon F; Tombal B; Van Cangh P; De Nayer P; Philippe M
    Clin Chem; 1998 Mar; 44(3):472-81. PubMed ID: 9510850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using "Light-Cycler"-based quantitative real-time polymerase chain reaction.
    Straub B; Müller M; Krause H; Schrader M; Goessl C; Heicappell R; Miller K
    Urology; 2001 Nov; 58(5):815-20. PubMed ID: 11711374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.